Drug
SCO-101
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Other(2)
Detailed Status
unknown2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
unknown2100%
Recent Activity
0 active trials
Showing 2 of 2
unknownphase_1
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
NCT04247256
unknownphase_1
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
NCT04652206
Clinical Trials (2)
Showing 2 of 2 trials
NCT04247256Phase 1
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
NCT04652206Phase 1
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2